Taro-Bortezomib 3.5 mg (Bortezomib (Bortezomib Mannitol Boronic Ester) POWDER FOR SOLUTION) 3.5 MG

Taro-Bortezomib 3.5 mg is a powder for solution used intravenously. It contains the active ingredient bortezomib, a proteasome inhibitor. This medication is often explored for its potential in managing certain cancers.

Strength

3.5 MG

Manufacturer / TM Owner

TARO PHARMACEUTICALS INC

Select Quantity

Pack/s

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

First Name

Last Name

Phone

Delivery Country

Delivery PostCode/Zipcode

Select Your Profile

I have read and agree to the terms & conditions, including the privacy policy, return policy, and usage terms as applicable to this request.

Indications & Clinical Uses

Taro-Bortezomib 3.5 mg is primarily used in the context of cancer treatment. It is a proteasome inhibitor, which may help in targeting specific cellular processes. The medication is often considered for conditions where proteasome inhibition is a therapeutic goal. Patients and healthcare providers may explore its use for various types of cancer, but specific applications should be discussed with a medical professional.

Side Effects

Common effects of Taro-Bortezomib 3.5 mg may include fatigue, nausea, and peripheral neuropathy. Some individuals might experience diarrhea or constipation. As with any medication, individual responses can vary, and it is important to monitor for any adverse reactions.

Precautions & Warnings

Taro-Bortezomib 3.5 mg should be handled with care, as it is intended for intravenous use. Proper preparation and administration by a healthcare professional are crucial. Patients should be aware of potential side effects and discuss any concerns with their healthcare provider. Storage and handling instructions should be followed to maintain the medication's integrity.

Avoid Interactions

Taro-Bortezomib 3.5 mg may interact with other medications, including those that affect liver enzymes. It is important to inform healthcare providers about all medications being taken to avoid potential interactions. Alcohol and certain supplements might also interact with bortezomib, so caution is advised.

Frequently Asked Questions

Taro-Bortezomib 3.5 mg is a proteasome inhibitor often explored for its potential in managing certain cancers.

Taro-Bortezomib 3.5 mg is administered intravenously after being prepared as a solution.

Common side effects may include fatigue, nausea, peripheral neuropathy, diarrhea, and constipation.

Potential interactions with other medications should be discussed with a healthcare provider to ensure safety.

Proper preparation and administration by a healthcare professional are crucial, and storage instructions should be followed.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated: 29 Jul 2026

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.